Desonide .5 mg/g Ointment — NDC 45802-423-37 (Billing 45802-0423-37)
This is a package of Desonide .5 mg/g Ointment from Padagis Israel Pharmaceuticals Ltd, marketed since Aug 2006 and currently FDA-listed; retail pharmacies pay about $0.2566 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 45802-423-37 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 45802 labeler · 423 product · 37 package
- Package marketed since
- Sep 18, 2006
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 4580242337 5
- Medicaid fills, this package
- 8,017 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007622
- GCN: 31430
- GPI-14 (Medi-Span): 90550035004205
- HICL (First Databank): 003322
- AHFS class code: 84:06.08.00
- RxCUI (RxNorm): 204135
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 8, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 8, 2026
Clinical
- It calms inflammation and itching from skin conditions that respond to steroids. The gel is specifically for mild to moderate eczema (atopic dermatitis) in people 3 months and olde...
- Put a thin layer on the affected skin and rub it in gently. How many times a day depends on your product, so follow your label and prescriber. Don’t cover the area with tight wraps...
- Use it for the shortest time that works. The gel should not go past 4 weeks in a row. The cream and ointment should not go past two weeks unless your doctor says so. Stop once your...
- Mild burning, rash, itching, dryness or irritation where you apply it. Call your doctor if the skin gets worse, thins, looks infected, or if you notice signs of too much steroid in...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Desonide — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.257 | $15.40 / 60 g |
| Medicaid paysCMS SDUD · 12 mo | $0.5299 | $31.79 / 60 g |
| Medicare drug plans payPart D · Q2 2026 | $0.6421 | $38.53 / 60 g |
Where does this data come from?
- CMS NADAC weekly file · file of Oct 7, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 45802-0423-35 45802-423-35 | 1 TUBE in 1 CARTON / 15 g in 1 TUBE | $0.3921 / g | $5.88 | 2006-08-22 | — | Active |
| 45802-0423-37 You're viewing this Main listing | 1 TUBE in 1 CARTON / 60 g in 1 TUBE | $0.2566 / g | $15.40 | 2006-09-18 | — | Active |
This pack has the lowest per-g cost of the 2 priced pack sizes ($0.2566 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 60% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Desonide .5 mg/g Ointment?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Desonide .5 mg/gthis 45802-0423-37 | Padagis | 1 tube | $0.257 | AB | Availability likely | — |
| Desonide .5 mg/g 00472-0804-15 | Actavis | 1 tube | $0.266 | AB | Discontinued | +4% |
| Desonide .5 mg/g 00713-0661-15 | Cosette | 1 tube | $0.306 | AB | Availability likely | +19% |
| Desonide .5 mg/g 16714-0729-01 | NORTHSTAR | 1 tube | $0.306 | AB | Availability likely | +19% |
| Desonide .5 mg/g 62332-0632-15 | Alembic | 1 tube | $0.306 | AB | Availability likely | +19% |
| Desonide .5 mg/g 51672-1280-01 | Sun | 1 tube | $0.306 | AB | Availability likely | +19% |
| Desonide .5 mg/g 72578-0086-01 | Viona | 1 tube | $0.306 | AB | Availability likely | +19% |
| Desonide Ointment, 0.05% .5 mg/g 21922-0004-04 | Encube | 1 tube | $0.392 | AB | Availability likely | +53% |
| Desonide .5 mg/g 51672-1281-01 | Sun | 1 tube | $0.392 | AB | Availability likely | +53% |
| Desonide .5 mg/g 62332-0485-15 | Alembic | 1 tube | $0.392 | AB | Availability likely | +53% |
| Desonide .5 mg/g 72603-0164-01 | NORTHSTAR | 1 tube | $0.392 | AB | Availability likely | +53% |
| Desonide .5 mg/g 46708-0485-15 | Alembic | 1 tube | — | AB | FDA listed | — |
| Desonide Ointment, 0.05% .5 mg/g 63629-8481-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide Ointment, 0.05% .5 mg/g 63629-8482-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide Ointment, 0.05% .5 mg/g 72162-1272-02 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 24470-0920-60 | Cintex | 1 tube | — | — | FDA listed | — |
| Desonide .5 mg/g 63187-0747-15 | Proficient | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 70771-1381-01 | Zydus | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 63629-2506-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 80425-0418-01 | Advanced | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 72162-2005-02 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 80425-0371-01 | Advanced | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 63629-2507-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desonide .5 mg/g 46708-0632-15 | Alembic | 1 tube | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Oct 7, 2026
Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Desonide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 4T6H12BN9U
Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Padagis Israel Pharmaceuticals Ltd labeler code 45802
- gynazole 1 butoconazole nitrate 100 mg/5g Cream NDC 45802-396-01
- Ciclopirox Olamine 7.7 mg/mL Suspension NDC 45802-400-46
- Ciclopirox 1 g/100mL Shampoo NDC 45802-401-09
- Alogliptin and Pioglitazone 25 mg; 30 mg Tablet, Film Coated NDC 45802-402-65
- oxymetazoline hcl oxymetazoline hydrochloride .05 g/100mL Spray NDC 45802-410-59
- Ammonium Lactate 12 g/100g Lotion NDC 45802-419-26
- pseudoephedrine hydrochloride Pseudoephedrine HCl 30 mg Tablet, Film Coated NDC 45802-432-62
- dextromethorphan polistirex extended release 30 mg/5mL Suspension NDC 45802-433-21
- clotrimazole 1 g/100g Cream NDC 45802-434-01
- TAZAROTENE .5 mg/g Gel NDC 45802-436-01
- Clobetasol Propionate .5 mg/g Aerosol, Foam NDC 45802-437-32
- hydrocortisone 1 g/100g Cream NDC 45802-438-03
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Desonide Ointment, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide Ointment, 0.05% should not be used with occlusive dressings.
⛔ Contraindications ▾
CONTRAINDICATIONS Desonide Ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Ointment, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids.
These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects: Pregnancy Category C - Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with Desonide Ointment, 0.05%.
It is also not known whether Desonide Ointment, 0.05% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide Ointment, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
🧒 Pediatric Use ▾
Pediatric Use - Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment.
Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
🆘 Overdosage ▾
OVERDOSAGE Topically applied Desonide Ointment, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called, lipocortins.
It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics - The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.
Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Studies performed with Desonide Ointment, 0.05% indicate that it is in the low range of potency as compared with other topical corticosteroids.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Desonide Ointment, 0.05% is available as follows: 15 g tube (NDC 45802- 423 -35) 60 g tube (NDC 45802- 423 -37)
📦 Storage and Handling ▾
STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
📋 Description ▾
DESCRIPTION Desonide Ointment, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11ß,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in Desonide Ointment, 0.05% is C 24 H 32 O 6 .
It has the following structural formula: The molecular weight of desonide is 416.51. It is a white to off-white powder. The solubility of desonide in distilled water saturated with ether is 184 mg/L.
Each gram of Desonide Ointment, 0.05% contains 0.5 milligram of desonide microdispersed in a base of white petrolatum. Perrigo Desonide Ointment
💬 Information for Patients ▾
Information for Patients Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.
Avoid contact with the eyes. 2. This medication should not be used for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician. 4.
Patients should report to their physician any signs of local adverse reactions.
⚠️ Precautions ▾
PRECAUTIONS General - Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression.
This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than two weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppressions. No specific studies relevant to potential HPA suppression have been conducted with Desonide Ointment, 0.05%.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids.
For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS - Pediatric Use ). If irritation develops, Desonide Ointment, 0.05% should be discontinued and appropriate therapy instituted.
Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used.
If a favorable response does not occur promptly, use of Desonide Ointment, 0.05% should be discontinued until the infection has been adequately controlled. Desonide Ointment, 0.05% should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy. Desonide Ointment, 0.05% should not be used in the eyes.
FOR EXTERNAL USE ONLY. Information for Patients Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician.
It is for external use only. Avoid contact with the eyes. 2.
This medication should not be used for any disorder other than that for which it was prescribed. 3. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.
4. Patients should report to their physician any signs of local adverse reactions. Laboratory Tests - The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of Desonide Ointment, 0.05%.
Pregnancy: Teratogenic Effects: Pregnancy Category C - Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with Desonide Ointment, 0.05%.
It is also not known whether Desonide Ointment, 0.05% can cause fetal harm when administered to a pregnan… [Excerpted — this section continues on DailyMed.]
🍼 Nursing Mothers ▾
Nursing Mothers - Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Desonide Ointment, 0.05% is administered to a nursing woman.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of Desonide Ointment, 0.05%.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - Carton NDC 45802-423-35 Rx Only Desonide Ointment, 0.05% NET WT 15 g The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation. carton serialization-template.jpg